Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib and Serplulimab in Advanced Solid Tumors with Neuroendocrine Differentiation
NCT06156332Phase 2Not yet recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
01
Overview
A Phase 2 trial of surufatinib, serplulimab in solid tumor, sponsored by Shanghai Changzheng Hospital. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
surufatinibserplulimab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06156332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06156332.